Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Nine Months Ended September 30, 2020 And Provid...
October 22 2020 - 2:00AM
UK Regulatory
TIDMVRP
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage
biopharmaceutical company focused on respiratory diseases, announces
that it will report its unaudited financial results for the three and
nine months ended September 30, 2020 on Thursday, October 29, 2020 and
host an investment community conference call at 9:00 a.m. EDT / 1:00
p.m. GMT to discuss these financial results and provide a corporate
update.
To participate, please dial one of the following numbers and reference
conference ID 2469127:
-- +1-888-317-6003 for callers in the United States
-- +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on
the Investors page of the Company's website, www.veronapharma.com, and
an audio replay will be available there for 90 days.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
------------------------------------------------------ ---------------------------
Victoria Stewart, Director of Communications info@veronapharma.com
------------------------------------------------------ ---------------------------
N+1 Singer Tel: +44 (0)20 7496 3000
(Nominated Adviser and UK Broker)
------------------------------------------------------ ---------------------------
Aubrey Powell / George Tzimas / Iqra Amin (Corporate
Finance)
------------------------------------------------------ ---------------------------
Tom Salvesen (Corporate Broking)
------------------------------------------------------ ---------------------------
Optimum Strategic Communications Tel: +44 (0)203 950 9144
(European Media and Investor Enquiries) verona@optimumcomms.com
------------------------------------------------------ ---------------------------
Mary Clark / Eva Haas / Shabnam Bashir
------------------------------------------------------ ---------------------------
Argot Partners Tel: +1 212-600-1902
(U.S. Investor Enquiries) verona@argotpartners.com
------------------------------------------------------ ---------------------------
Kimberly Minarovich / Michael Barron
------------------------------------------------------ ---------------------------
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. If
successfully developed and approved, Verona Pharma's product candidate,
ensifentrine, has the potential to be the first therapy for the
treatment of respiratory diseases that combines bronchodilator and
anti-inflammatory activities in one compound. The Company is evaluating
nebulized ensifentrine in its Phase 3 clinical program ENHANCE
("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD
maintenance treatment. The Company raised gross proceeds of $200 million
through a private placement in July 2020 and expects the funds to
support its operations and Phase 3 clinical program into 2023. Two
additional formulations of ensifentrine are currently in Phase 2
development for the treatment of COPD: dry powder inhaler ("DPI") and
pressurized metered-dose inhaler ("pMDI"). Ensifentrine is in a pilot
clinical study in patients hospitalized with COVID-19 and has potential
applications in cystic fibrosis, asthma and other respiratory diseases.
For more information, please visit www.veronapharma.com.
(END) Dow Jones Newswires
October 22, 2020 02:00 ET (06:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Dec 2024 to Jan 2025
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jan 2024 to Jan 2025
